Table 2.

The type-specific prevalence of HPV in HNSCCs by cancer site

Oral cavity* (n = 2,642)
Oropharynx* (n = 969)
Larynx*, (n = 1,435)
Positive/testedPrevalence (%)Positive/testedPrevalence (%)Positive/testedPrevalence (%)
659/1,8843.118/7062.552/1,0285.1
1131/1,9041.65/7050.75/1,0150.5
16423/2,64216.0299/96930.9238/1,43516.6
18212/2,6428.09/9091.054/1,3873.9
16 and 1844/2,6421.71/9090.16/1,3870.4
313/1,4220.20/6560.02/7970.3
321/4960.20/2870.00/1780.0
3314/1,6780.89/8021.19/1,0510.9
351/1,3500.12/5680.40/4960.0
390/1,3350.00/4960.00/3000.0
441/1,2900.10/4660.00/2910.0
450/1,3620.01/5590.21/4390.2
510/1,3500.00/5680.01/3360.3
520/1,3350.00/4960.01/4430.2
531/5390.20/3290.00/3270.0
562/1,3500.10/5680.00/2960.0
571/3930.30/2200.00/2630.0
581/1,3350.10/5630.00/4430.0
590/1,3350.01/4960.20/3000.0
681/1,3350.10/4960.00/2600.0
730/5240.00/2250.00/2060.0
811/4050.20/2200.00/1780.0
820/4960.00/2200.00/1780.0
  • NOTE: HPV types considered “high-risk” are in bold.

    Abbreviations: HPV, human papillomaviruses; HNSCCs, head and neck squamous cell carcinomas.

  • * Columns do not sum to total number of HPV-positive cases because multiple infections were broken down into constituent types. Columns sum to total number of infections in study population.

  • Larynx includes cases of the hypopharynx.

  • HPV types considered to confer low or intermediate risk based on cervical cancer studies (4).